Robert (Bob) Abraham, Ph.D. is Senior Vice President and Chief Scientific Officer of Pfizer’s Oncology Research Unit. This group is at the forefront of breaking new ground to develop impactful, life-saving cancer therapies and spearheading the company’s Precision Medicine approach to R&D.
“This is an incredibly exciting time to be involved in cancer research and drug development. Advances in technology are providing unprecedented insights into the biological underpinnings of this complex disease, and are opening entire approaches to attack specific vulnerabilities in tumor cells. The promise of more effective, safer cancer medicines is further enhanced by the rapidly evolving field of precision medicine, which allows us to deliver innovative new drugs to patients whose tumors bear molecular signatures indicative of optimal responsiveness to these agents.”
Senior Vice President and Chief Scientific Officer, Oncology Research Unit
Robert (Bob) Abraham, Ph.D., is Senior Vice President and Chief Scientific Officer for the Oncology Research Unit, where he is responsible for overseeing the discovery of new candidates for the treatment of cancer.
Prior to this role, Dr. Abraham served as the Vice President of Oncology Research at Wyeth and Co-Chair of the Wyeth Oncology Therapeutic Area Strategic Committee. While at Wyeth, he also served as a member of the Discovery Review Board and the Discovery Executive Committee, and was the Director of the Wyeth Discovery Postdoctoral Training Program.
Prior to joining Wyeth, Dr. Abraham was a professor at The Sanford-Burnham Institute for Medical Research (SBIMR) in La Jolla, California. He served as the Director of the SBIMR Cancer Research Center and successfully guided the center to a renewal of its designation as one of nine National Cancer Institute-sponsored basic science centers in the United States.
Dr. Abraham also founded and directed the program in Signal Transduction Research in the SBIMR Cancer Center, and retains an appointment as an Adjunct Professor at the SBIMR, together with an Adjunct Professor Appointment in Pharmacology at the University of California, San Diego. Previously, Dr. Abraham was a professor in the Department of Pharmacology and Cancer Biology at Duke University Medical Center, and was the first recipient of the Glaxo-Wellcome Chair of Molecular Cancer Biology at Duke. Before his arrival at Duke University, Dr. Abraham worked at the Mayo Clinic as a professor and postdoctoral fellow in immunology and pharmacology.
Dr. Abraham received his Ph.D. in pharmacology at the University of Pittsburgh, and his B.S. in biology from Bucknell University. He is the author of more than 200 scientific publications in peer-reviewed journals, and has served on and chaired grant review panels at the National Institutes of Health. He is a reviewer for many leading scientific journals, including Nature, Science, and Cell.
Dr. Abraham has received several awards for both his teaching and research contributions, including the Legacy Laureate Award, as an outstanding alumnus of the University of Pittsburgh.